7,221 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Cibc World Market Inc.

Posted by Francis Steltz on Aug 27th, 2026

Cibc World Market Inc. acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 7,221 shares of the biopharmaceutical company’s stock, valued at approximately $2,174,000.

A number of other hedge funds have also added to or reduced their stakes in the business. OMERS ADMINISTRATION Corp bought a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at about $1,360,000. Osmosis Investment Management UK Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at $1,095,000. Sanctuary Advisors LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at about $945,000. Polymer Capital Management HK LTD acquired a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $19,554,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at $200,000. Institutional investors own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares in the company, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $239.00 on Thursday. The company has a 50 day simple moving average of $264.27 and a 200 day simple moving average of $294.77. The stock has a market cap of $31.98 billion, a price-to-earnings ratio of 44.42 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 1 year low of $197.81 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. The firm had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company’s quarterly revenue was up 66.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.51) earnings per share. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. JPMorgan Chase & Co. decreased their target price on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Wells Fargo & Company decreased their price target on Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating on the stock in a research report on Friday, August 14th. Stifel Nicolaus dropped their price target on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Raymond James Financial raised shares of Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price objective for the company in a research report on Monday, August 3rd. Finally, Royal Bank Of Canada reduced their price objective on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $386.14.

Check Out Our Latest Stock Report on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.